Applied DNA Sciences, Inc. (NASDAQ:APDN) to Post Q3 2024 Earnings of ($0.64) Per Share, HC Wainwright Forecasts

Applied DNA Sciences, Inc. (NASDAQ:APDNFree Report) – Analysts at HC Wainwright boosted their Q3 2024 earnings estimates for Applied DNA Sciences in a report issued on Monday, June 10th. HC Wainwright analyst Y. Chen now expects that the technology company will earn ($0.64) per share for the quarter, up from their prior forecast of ($1.51). HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for Applied DNA Sciences’ current full-year earnings is ($6.54) per share. HC Wainwright also issued estimates for Applied DNA Sciences’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($2.95) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.85) EPS.

Applied DNA Sciences (NASDAQ:APDNGet Free Report) last released its quarterly earnings results on Friday, May 10th. The technology company reported ($5.31) earnings per share for the quarter, missing the consensus estimate of ($4.60) by ($0.71). Applied DNA Sciences had a negative return on equity of 306.32% and a negative net margin of 222.33%. The business had revenue of $0.93 million during the quarter, compared to the consensus estimate of $0.90 million.

Separately, started coverage on shares of Applied DNA Sciences in a research note on Friday, May 31st. They issued a “hold” rating for the company.

Check Out Our Latest Report on APDN

Applied DNA Sciences Price Performance

Shares of NASDAQ APDN opened at $0.53 on Wednesday. The firm has a fifty day moving average price of $3.58 and a 200-day moving average price of $9.31. The stock has a market cap of $520,674.00, a PE ratio of -0.03 and a beta of 0.08. Applied DNA Sciences has a 1 year low of $0.48 and a 1 year high of $37.20.

Hedge Funds Weigh In On Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of Applied DNA Sciences, Inc. (NASDAQ:APDNFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned approximately 0.72% of Applied DNA Sciences at the end of the most recent reporting period. 22.22% of the stock is currently owned by institutional investors.

Applied DNA Sciences Company Profile

(Get Free Report)

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.

Featured Articles

Earnings History and Estimates for Applied DNA Sciences (NASDAQ:APDN)

Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with's FREE daily email newsletter.